Interview with Dominique Amory, President, Lilly France
There is a lot of activity in the pharmaceutical industry and France is no exception especially having passed Germany as the major market of Europe over the past year which…
Address: 24 Boulevard Vital Bouhot
CS 50004
92521 Neuilly-sur-Seine Cedex
Tel: 01 55 49 34 34
Web: http://www.lilly.com/Pages/home.aspx
The Pharmaceutical company Lilly has been in France since 1962. This is the 4th subsidiary of Lilly after the United States, Japan and Germany.
Lilly France is the 16th French pharmaceutical company and has a turnover of 2.3 billion euros in 2008, including 1.6 billion under its manufacturing (factory Fegersheim).
Advancing medicine, contributing to major therapeutic advances, allowing everyone to live better and longer: this is the mission of the pharmaceutical company Lilly.
Eli Lilly and Company is a specialty pharmaceutical company entirely focused on innovation and committed to developing a portfolio of drugs to both the best and the first in their class, to allow patients to be healthier and live a longer and more active.
To do this, we use the results of recent medical studies in our laboratories pharmaceutical world. We are collaborating with eminent scientific organizations, and we appeal to the most advanced technological tools, while ensuring the high quality service to our customers.
Through internal programs and external initiatives, we intend to meet the most urgent medical needs. Lilly employs more than 40 450 people worldwide and markets its medicines in 143 countries. The company has major research and development centers in 9 countries and conducts clinical trials in over 50 countries.
Lilly’s drugs treat depression, schizophrenia, cancer, diabetes, osteoporosis and other disorders.
There is a lot of activity in the pharmaceutical industry and France is no exception especially having passed Germany as the major market of Europe over the past year which…
The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that…
See our Cookie Privacy Policy Here
